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In this data article we present data on the distribution of alleles
and genotypes of the interleukin (IL)-6 c.-174 G4C polymorphism
(rs 1800795) in patients with coronary heart disease (CHD) in
dependence of the incidence of new cardiovascular events (com-
bined endpoint: myocardial infarction, stroke/TIA, cardiac death,
death according to stroke) within three years follow-up. Moreover,
we investigated putative associations between individual expres-
sion of IL-6 genotypes and IL-6 serum level. This investigation is a
subanalysis of the article entitled “The Interleukin 6 c.-174 CC
genotype is a predictor for new cardiovascular events in patients
with coronary heart disease within three years follow-up“ (Clin-
icalTrials.gov identiﬁer: NCT01045070) (Reichert et al., 2016) [1].
& 2016 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).vier Inc. This is an open access article under the CC BY license
/j.cyto.2016.04.011
Reichert).
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ow data was
acquiredVenous EDTA-blood (IL-6 genotyping, IL-6 serum level), standardized ques-
tionnaire for acquire follow-up dataata format Analyzed
xperimental
factorsVenous blood for genetic and serologic analyses was acquired at baseline during
in-patient phase. New cardiovascular events were evaluated within three years
follow-upxperimental
featuresIL-6 genotyping was carried out with PCR-SSPata source
locationMartin-Luther University Halle-Wittenberg Department for Operative Dentistry
and Periodontologyata accessibility Data are within this article.DValue of the data Previously unreported data about the distribution of IL-6 c.-174 G4C genotypes among German
patients with cardiovascular disease in relation to the incidence of new cardiovascular events
 Data may stimulate further research in order to identify new biomarkers for cardiovascular out-
come [2–4].
 Data may improve the development of individual therapeutic strategies in order to prevent new
adverse events in patients with coronary heart disease.1. Data
Patients who were carrier of the IL-6 c.-174 CC genotype suffered more frequently from a new
cardiovascular event whereas carriers of the genotype CG experienced the combined endpoint less
often. There was no signiﬁcant association between the genotype GG and incidence of the combined
endpoint (Table 1). Regarding the allele distribution we obtained a positive association between C
allele and new adverse events (Table 2). There were no signiﬁcant differences regarding IL-6 serum
levels between carriers of the genotypes GG, CG, and CC (Fig. 1).es in dependence of the incidence of the combined endpoint (myocardial infarction, Transient
iovascular death or death according to stroke). Statistical comparisons were made by Chi-square
e higher frequency of CC carriers among patients with new cardiovascular events.
All patients
(n¼895) %
No event
(n¼751) %
Event
(n¼144) %
p-Value
21.5 19.2 33.3↑
78.5 80.8 66.7 o0.0001
48.8 50.7 38.9
51.2 49.3 61.1 0.009
29.7 30.1 27.8
70.3 69.9 72.2 0.578
Table 2
Distribution of IL-6 alleles in dependence of the incidence of the combined endpoint (myocardial infarction, transient ischemic
attack/stroke, cardiovascular death or death according to stroke). Statistical comparisons were made by Chi-square test. The
arrow indicates the higher frequency of C carriers among patients with new cardiovascular events.
IL-6 174
G4C
alleles
All patients
chromosomes
(n¼1790) %
No event chro-
mosomes
(n¼1502) %
Event chromo-
somes (n¼288)
%
p-Value
G 54.1 55.5 47.2
C 45.9 44.5 52.8↑ 0.010
Fig. 1. Boxplots of IL-6 serum levels in dependence of the individual expression of the IL-6 c.-174 G4C genotypes GG, CG and
CC. Statistical comparison was made with Kruskal–Wallis test.
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2.1. Patient group at baseline
The investigation was carried out in accordance with the ethical guidelines of the “Declaration of
Helsinki” and its amendment in “Tokyo and Venice” and were approved by the local ethics
committee.
This subanalysis comprised 942 in-patients with CHD (age 66.8711.01 years, males 74%) at study
entry from October 2009 to February 2011. Inclusion criteria were age Z18 years and known CHD as
deﬁned by a stenosis of Z50% of a main coronary artery by coronary angiography or percutaneous
coronary intervention (PCI) or coronary artery bypass surgery (CABG). At least four own teeth except
for the third molars needed to be present. Exclusion criteria were pregnancy, antibiotic therapy
during the last 3 months, subgingival scaling and root planing during the last 6 months or psycho-
logical reasons rendering study participation impractical. Patients with current alcohol or drug abuse
might be not completely able to understand the aim of the study and the necessity of an additional
dental examination. If a drug or alcohol abuse was known from patient's ﬁle or a patient reported
during the interview about a current drug or alcohol abuse he/she was not included in the study.
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A follow-up was performed after three years from November 2013 to January 2015. The incidence
of the predeﬁned combined endpoint (combined endpoint: myocardial infarction, stroke/transient
ischemic attack, cardiac death, death caused by stroke) was calculated. This information was obtained
from electronic patient ﬁles, physicians, relatives, and civil registration ofﬁces. For acquiring follow-
up data we sent out a standardized questionnaire. If patients did not return the questionnaires, we
conducted a telephone interview with the patient or his/her relatives or contacted the patient's
physician. If follow-up information could not be obtained from these persons, we contacted civil
registration ofﬁces and requested information about current address or date of death.
From 895 of 942 initial included patients follow-up data were available (drop-out rate 4.9%) after
three years follow-up (153.4748.8 weeks). The incidence of the combined endpoint was 16.1%.2.3. Determination of IL-6 serum level and c.-174 IL-6 polymorphism
Blood samples for determination of IL-6 serum level and IL-6 genotyping were taken at begin of
the study from all study participants during their hospital stay. Serum level for IL-6 was determined
with electrochemiluminescent immunoassay (ECLIA) using a Cobas e 602 module (Roche Diagnostics)
in the central laboratory of University Clinics Halle (Saale).
The determination of IL-6 c.-174 G4C polymorphism was carried out with PCR-SSP (sequence
speciﬁc oligonucleotides) using the CYTOKINE Genotyping array CTS-PCR-SSP kit (Collaborative
Transplant Study, Department of Transplantation Immunology of the University Clinic of Heidelberg,
Germany) in the laboratory of the Department of Operative Dentistry and Periodontology.2.4. Statistical analyses
Statistical analyses were carried out using commercial available software (SPSS v.20.0 package,
IBM, Chicago, IL). The IL-6 genotype and allele frequencies were calculated by direct counting and
then dividing by the number of subjects to produce genotype frequency, or by the number of chro-
mosomes to produce allele frequency. Differences between patients and controls were determined by
chi-square test. The values for IL-6 serum level were checked for normal distribution using the
Kolmogorov–Smirnov test and the Shapiro-Wilk test. As they were not normally distributed, com-
parisons in dependence of IL-6 genotypes were carried out with Kruskal–Wallis test. In general, p
values r0.05 were accepted as statistically signiﬁcant.Acknowledgements
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